PATENT COOPERATION TRE/ ~~?

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION CONCERNING
TRANSMITTAL OF COPY OF INTERNATIONAL
PRELIMINARY REPORT ON PATENTABILITY
(CHAPTER I OF THE PATENT COOPERATION
TREATY)

(PCT Rule 44bis.1(c))

To

MYERS BIGEL SIBLEY & SAJOVEC, P.A. P.O. Box 37428
Raleigh, North Carolina 27627
ETATS-UNIS D'AMERIQUE

Date of mailing (day/month/year)
18 October 2007 (18.10.2007)

Applicant's or agent's file reference 5470.398.WO

IMPORTANT NOTICE

International application No. PCT/US2004/030987

International filing date (day/month/year) 21 September 2004 (21.09.2004)

Priority date (day/month/year)
22 September 2003 (22.09.2003)

Applicant

UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL et al

The International Bureau transmits herewith a copy of the international preliminary report on patentability (Chapter I of the Patent Cooperation Treaty)

10

2:14 IN

10-25-07 A09:14 IN

DOCKETED

By 50

Date 10/25

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

Authorized officer

Beate Giffo-Schmitt

Facsimile No. +41 22 338 82 70

e-mail: pt03.pct@wipo.int

PATENT COOPERATION TREAT.

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44bis)

Applicant's or agent's file reference 5470.398.WO	FOR FURTHER ACTION	See item 4 below			
International application No. PCT/US2004/030987	International filing date (day/month/year) 21 September 2004 (21.09.2004)	Priority date (day/month/year) 22 September 2003 (22.09.2003)			
International Patent Classification (8th edition unless older edition indicated) See relevant information in Form PCT/ISA/237					
Applicant UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL					

1.	This international preliminary report on patentability (Chapter I) is issued by the International Bureau on behalf of the International Searching Authority under Rule 44 <i>bis</i> .1(a).				
2.	This REPORT consists of a total of 5 sheets, including this cover sheet.				
	In the attached sheets, any reference to the written opinion of the International Searching Authority should be read as a reference to the international preliminary report on patentability (Chapter I) instead.				
3.	This report contains indication	ns relating to the following items:			
	Box No. I	Basis of the report			
	Box No. II	Priority			
	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability			
	Box No. IV	Lack of unity of invention			
	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement			
	Box No. VI	Certain documents cited			
	Box No. VII	Certain defects in the international application			
	Box No. VIII	Certain observations on the international application			
4.	The International Bureau will not, except where the applicar date (Rule 44bis .2).	communicate this report to designated Offices in accordance with Rules 44bis.3(c) and 93bis.1 but it makes an express request under Article 23(2), before the expiration of 30 months from the priority			

Authorized officer

e-mail: pt03.pct@wipo.int

Beate Giffo-Schmitt

Facsimile No. +41 22 338 82 70 Form PCT/IB/373 (January 2004)

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

PATENT COOPERATION TREATY

From the NTERNATIONAL SEARCHING AUTHOR	TY				
To: KAREN A. MAGRI MYERS BIGEL SIBLEY & SAJOVEC. P.A. P.O. BOX 37428 RALEIGH, NC 27627		PCT			
		WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY			
			(PCT Rule 43bis.1)		
		Date of mailing (dav/month/year)	2 5 SEP 2007		
Applicant's or agent's file reference		FOR FURTHER ACTION			
5470.398.WO		See paragraph 2 below			
International application No. In	ternational filing date	(day/month/year)	Priority date (day/month/year)		
	September 2004 (21.		22 September 2003 (22.09.2003)		
International Patent Classification (IPC) or be					
IPC: C12Q 1/56(2006.01)					
USPC: 435/13 Applicant					
•••					
UNIV. OF NORTH CAROLINA AT CHAP	EL HILL				
1. This opinion contains indications relating	to the following item	ıs:			
N 7	•				
Box No. I Basis of the opi	nion				
Box No. II Priority					
Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability					
Box No. IV Lack of unity of	Box No. IV Lack of unity of invention				
Box No. V Reasoned stater applicability; ci	o. V Reasoned statement under Rule 43 bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
Box No. VI Certain docume	nts cited				
Box No. VII Certain defects	in the international ap	plication			
Box No. VIII Certain observa	tions on the internation	nai application			
2. FURTHER ACTION					
International Preliminary Examining A	uthority ("IPEA") ex PEA and the chosen	ccept that this does IPEA has notified to	be considered to be a written opinion of the s not apply where the applicant chooses an he International Bureau under Rule 66.1bis(b) lered.		
If this opinion is, as provided above, co IPEA a written reply together, where apply of Form PCT/ISA/220 or before the expired the second seco	propriate, with amend	ments, before the ex	PEA, the applicant is invited to submit to the expiration of 3 months from the date of mailing whichever expires later.		
For further options, see Form PCT/ISA/2					
3. For further details, see notes to Form PCT	7/ISA/220.				
Name and mailing address of the ICA/IIC	D. L.				
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US	Date of complet	tion of this opinion	Authorized officer		
Commissioner for Patents 04 August 200 P.O. Box 1450		(04.08.2007)	Satyendra K. Sirgal		
Alexandria, Virginia 22313-1450			Telephone No. 571-272-8790		
grimile No. (571) 272 2201	i		p		

Facsimile No. (571) 273-3201
Form PCT/ISA/237 (cover sheet) (April 2005)

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.
PCT/US04/30987

Box No. I Basis of this opinion						
	gard to the language, this opinion has been established on the basis of: the international application in the language in which it was filed translation of the international application into, which is the language of a translation furnished for the purposes of					
i	nternational search (Rules 12.3(a) and 23.1(b)).					
With re invention	2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:					
a.	a. type of material					
	a sequence listing					
;	table(s) related to the sequence listing					
b.	format of material					
	on paper					
	in electronic form					
c.	time of filing/furnishing					
	contained in the international application as filed.					
	filed together with the international application in electronic form.					
	furnished subsequently to this Authority for the purposes of search.					
	In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.					
4. Additio	nal comments:					
	•					
•						

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.
PCT/US04/30987

Box N	o. II Priority
1.	The validity of the priority claim has not been considered because the International Searching Authority does not have in its possession a copy of the earlier application whose priority has been claimed or, where required, a translation of that earlier application. This opinion has nevertheless been established on the assumption that the relevant date (Rules 43bis.1 and 64.1) is the claimed priority date.
2.	This opinion has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid (Rules 43bis.1 and 64.1). Thus for the purposes of this opinion, the international filing date indicated above is considered to be the relevant date.
This ir	al observations, if necessary: nternational search authority acknowledges applicant's claim for priority over US provisional application US 60504796 filed on otember 2003.

Form PCT/ISA/237 (Box No. II) (April 2005)

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/US04/30987

Box No. V Reasoned statement under Rule 43 bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
1. Statement				
Novelty (N)	Claims	3-49	YES	
	Claims	1-2	NO	
Inventive step (IS)	Claims	NONE	YES	
	Claims	1-49	NO	
Industrial applicability (IA)	Claims	1-49	YES	
	Claims	NONE	No	
2. Citations and explanations: Claims 1 and 2 lack novelty under PCT Article 33(1 method of evaluating clotting activity comprising: Triplett et al, abstract, summary of the invention, explain paragraph, in particular), a contact activator and particular), incubating said mixture for a time and use (by the release of p-nitroaniline that is measured phenomenature of the claims I-49 lack an inventive step under PCT Article Triplett et al (US 5,705,198); Speck (US 3,486,981) 6,395,501 B1); Dai et al (US 2003/0073071 A1); are	combining a plas camples 4 and 5, calcium chlorid- inder conditions otometrically) we ble 33(3) as being); Matschiner (Und Wang et al (U	ma sample (from patients containing lup- in particular), a soluble phospholipid (se e (see Chromogenic Test for thrombin ac sufficient for thrombin activation, and de thich is indicative of clotting factor active g obvious over the following prior art cit S 5.525.478): Kraus (US 2002/0019021	ous anticoagulant, LA; see ee Triplett et al, column 5, ctivity, example 5, in letecting thrombin activity rity in the sample.	

Claims are generally directed to various methods (including a composition, and a kit) of evaluating clotting activity, or clotting time based on thrombin or clotting factor activity in blood or plasma samples. The prior art relied upon by the Examiner discloses a generic method (as discussed above, Triplett et al.) for evaluating the clotting activity of blood or plasma from patient sample. In addition, various components used in the method, such as contact activator (see Speck, columns 3-4; uses ellagic acid; Rosen et al, see claims 26-27, in particular), activated protein C or APC and protein S depleted plasma, various phospholipids, tissue factor and other clotting factors, various standards and controls, and kits comprising said reagents for performing said clotting assay (see Matschiner, abstract, figures 1-4, examples; Kraus, abstract, pages 3-4, page 5 [0051]; Rosen et al, abstract, columns 7-9 and 10-12, examples and claims; Dai et al, abstract, example 5 and claims; and Wang et al, abstract, column 2-3, in particular) have been fully disclosed in the cited prior art. Therefore, it would have been obvious to a person of ordinary skill in the art to modify the methods of Triplett et al or Speck using/substituting the components already known in the art to arrive at the invention (methods as well as a composition and a kit) as

Claims 1-49 meet the criteria set out in PCT Article 33(4), and thus claims 1-49 have industrial applicability because the subject matter

claimed with a reasonable expectation of success. Thus, the entire invention as claimed lacks an inventive step.

claimed can be made or used in industry.

Form PCT/ISA/237 (Box No. V) (April 2005)